# Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

> **NCT00082381** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 551 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Exenatide (AC2993)
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT00082381
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2015-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082381, "Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00082381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*